Circulation. It keeps your body alive, your blood moving, and your retirement dreams chasing 10,000 steps. But what happens when the very thing keeping you alive starts to betray you, slowly, quietly, molecule by molecule?
Enter Circulate Health, a biotech startup out of Novato, California, that just stepped out of stealth mode and into a $12 million seed round led by the sharp minds at Khosla Ventures, with support from Seaside Ventures and CSC Upshot Ventures. Not bad for a company that’s been quietly building a playbook on how to not just live longer, but live better.
This isn’t another injection of hope and hashtags. Circulate Health is flipping the bloodstream into a battleground. Their weapon of choice? A patented therapeutic plasma exchange (TPE) platform that removes inflammatory, toxic, age-accelerating substances from your plasma. Then they replace it with clean, regulated fluids like cleaning out a fish tank, except the fish is you and the water is what’s keeping your mitochondria from phoning it in.
Let’s talk leadership. CEO and co-founder Dr. Brad Younggren isn’t your usual lab coat. He’s a U.S. Army combat physician with a Bronze Star and enough frontline trauma experience to make a Netflix series nervous. His co-founder Dr. Eric Verdin is the President and CEO of the Buck Institute for Research on Aging, a literal walking textbook on geroscience. The man’s got a resume that could bio-age you just by reading it.
Together, they didn’t just build a startup, they built a movement. Since quietly launching in early 2024, Circulate Health has grown from zero to 24 partner clinics across 8 states, with plans to hit 50 by year’s end. They’ve already delivered over 1,000 treatments. And their first peer-reviewed clinical trial? Published in Aging Cell, 42 participants, 240 TPE+IVIG procedures, 0.42% adverse events, and a 2.61-year drop in biological age. That’s not a headline, that’s a mic drop.
While most in longevity are chasing theories and mouse models, Circulate Health is running live ops in the human body. They’re layering in multi-omics biomarker analysis, biweekly/monthly treatment protocols, and a safety profile that would make a cardiologist smile. This isn’t science fiction, it’s science done right, backed by one of the most respected aging research institutions in the world.
Now, let’s talk business. Individual TPE sessions clock in at $8K–$10K. Not covered by insurance. And yet? Demand is accelerating. Because longevity medicine isn’t a trend, it’s a tectonic shift. The anti-senescence market is expected to hit $38.36B by 2029, and Circulate’s plasma-centric approach could be the artery through which it flows.
This is what happens when precision medicine meets military-grade execution and billion-dollar science. Congrats to Brad Younggren, Eric Verdin, and the Circulate team. You’re not just extending healthspan, you’re expanding what’s possible.
